154 related articles for article (PubMed ID: 15123220)
21. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease.
Zhong N; Zheng J; Wen F; Yang L; Chen P; Xiu Q; Yao W; Sun T; Zhao Z; Shen H; Shi Y; Lin J; Li Q
Curr Med Res Opin; 2012 Feb; 28(2):257-65. PubMed ID: 22046961
[TBL] [Abstract][Full Text] [Related]
22. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease.
Campbell M; Eliraz A; Johansson G; Tornling G; Nihlén U; Bengtsson T; Rabe KF
Respir Med; 2005 Dec; 99(12):1511-20. PubMed ID: 16199148
[TBL] [Abstract][Full Text] [Related]
23. Bronchodilator effects of indacaterol and formoterol in patients with COPD.
Beier J; Beeh KM; Brookman L; Peachey G; Hmissi A; Pascoe S
Pulm Pharmacol Ther; 2009 Dec; 22(6):492-6. PubMed ID: 19465142
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflation.
Santus P; Centanni S; Verga M; Di Marco F; Matera MG; Cazzola M
Respir Med; 2006 Jul; 100(7):1277-81. PubMed ID: 16337781
[TBL] [Abstract][Full Text] [Related]
25. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial.
Calverley PM; Kuna P; Monsó E; Costantini M; Petruzzelli S; Sergio F; Varoli G; Papi A; Brusasco V
Respir Med; 2010 Dec; 104(12):1858-68. PubMed ID: 20965712
[TBL] [Abstract][Full Text] [Related]
26. Onset of effect of budesonide and formoterol administered via one pressurized metered-dose inhaler in patients with asthma previously treated with inhaled corticosteroids.
Kaiser H; Parasuraman B; Boggs R; Miller CJ; Leidy NK; O'Dowd L
Ann Allergy Asthma Immunol; 2008 Sep; 101(3):295-303. PubMed ID: 18814453
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of high-dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma.
Jenkins C; Kolarikova R; Kuna P; Caillaud D; Sanchis J; Popp W; Pettersson E
Respirology; 2006 May; 11(3):276-86. PubMed ID: 16635085
[TBL] [Abstract][Full Text] [Related]
28. Budesonide/formoterol Turbuhaler®: a review of its use in chronic obstructive pulmonary disease.
Scott LJ
Drugs; 2012 Feb; 72(3):395-414. PubMed ID: 22316354
[TBL] [Abstract][Full Text] [Related]
29. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma.
Tal A; Simon G; Vermeulen JH; Petru V; Cobos N; Everard ML; de Boeck K
Pediatr Pulmonol; 2002 Nov; 34(5):342-50. PubMed ID: 12357478
[TBL] [Abstract][Full Text] [Related]
30. Budesonide/formoterol: in chronic obstructive pulmonary disease.
Reynolds NA; Perry CM; Keating GM
Drugs; 2004; 64(4):431-41; discussion 433-4. PubMed ID: 14969576
[TBL] [Abstract][Full Text] [Related]
31. Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma.
Ankerst J; Persson G; Weibull E
Pulm Pharmacol Ther; 2003; 16(3):147-51. PubMed ID: 12749830
[TBL] [Abstract][Full Text] [Related]
32. The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol.
Goldkorn A; Diotto P; Burgess C; Weatherall M; Holt S; Beasley R; Siebers R
Respirology; 2004 Mar; 9(1):102-8. PubMed ID: 14982610
[TBL] [Abstract][Full Text] [Related]
33. Effect of formoterol with or without budesonide in repeated low-dose allergen challenge.
Dahlén B; Lantz AS; Ihre E; Skedinger M; Henriksson E; Jörgensen L; Ekström T; Dahlén SE; Larsson K
Eur Respir J; 2009 Apr; 33(4):747-53. PubMed ID: 19129280
[TBL] [Abstract][Full Text] [Related]
34. Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations.
Bathoorn E; Liesker JJ; Postma DS; Boorsma M; Bondesson E; Koëter GH; Kauffman HF; van Oosterhout AJ; Kerstjens HA
COPD; 2008 Oct; 5(5):282-90. PubMed ID: 18972276
[TBL] [Abstract][Full Text] [Related]
35. Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety.
Bodzenta-Lukaszyk A; Buhl R; Balint B; Lomax M; Spooner K; Dissanayake S
J Asthma; 2012 Dec; 49(10):1060-70. PubMed ID: 23102189
[TBL] [Abstract][Full Text] [Related]
36. Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: A SOMA study.
Haahtela T; Tamminen K; Malmberg LP; Zetterström O; Karjalainen J; Ylä-Outinen H; Svahn T; Ekström T; Selroos O
Eur Respir J; 2006 Oct; 28(4):748-55. PubMed ID: 17012630
[TBL] [Abstract][Full Text] [Related]
37. Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients.
Cazzola M; Mantero A; Santus P; Carlucci P; Mondoni M; Bosotti L; Centanni S
Pulm Pharmacol Ther; 2007; 20(3):258-64. PubMed ID: 16600647
[TBL] [Abstract][Full Text] [Related]
38. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.
Pauwels RA; Löfdahl CG; Postma DS; Tattersfield AE; O'Byrne P; Barnes PJ; Ullman A
N Engl J Med; 1997 Nov; 337(20):1405-11. PubMed ID: 9358137
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study.
Panettieri RA; MacIntyre N; Sims M; Kerwin E; Fogarty C; Noonan M; Claus R; Andrews WT
Clin Ther; 2009 Aug; 31(8):1716-23. PubMed ID: 19808130
[TBL] [Abstract][Full Text] [Related]
40. Inhaled steroid/long-acting beta 2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients.
Lötvall J; Langley S; Woodcock A
Respir Res; 2006 Aug; 7(1):110. PubMed ID: 16919161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
